Cancer-related FLT3 mutations in leukemia, especially acute myeloid leukemia (AML), can induce ligand-independent activation of the receptor and promote proliferation of hematological tumor cells2–4. This evidence concerns the gene FLT3 and acute myeloid leukemia.